We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Cancer Drug Keytruda Positive in Clinical Studies
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high levels of PD-L1.
In Aug 2016, Keytruda was approved in the EU for second-line treatment of advanced or metastatic NSCLC in patients with tumors expressing PD-L1 and who have received at least one prior chemotherapy regimen.
Incidentally, the drug is already approved in the U.S. for first-line NSCLC indication. In fact, its sales figures are projected to sharply improve, following the latest approval which would allow Keytruda to be marketed in all 28 member countries of the EU apart from Iceland, Lichtenstein and Norway.
Investors must be reminded that in addition to healing lung cancer, Keytruda is approved in the U.S. for treating patients with unresectable or metastatic melanoma. The drug can be administered until the disease progresses or the toxicity level reaches an unacceptable point.
Also, the medicine comes handy for patients whose previously treated metastatic head and neck cancer (HNSCC) relapses.
Merck’s share price movement shows the stock to outperform the Zacks classified Large Cap Pharma industry in the last year. The stock climbed 14.1% compared to industry’s 2.4% increase during the period.
With approximately eight additional months of follow-up, data from the KEYNOTE-024 study demonstrated a superior overall survival (OS) and progression-free survival (PFS) of Keytruda compared to chemotherapy.
The study showed an 18-month OS rate of 61.2% in the Keytruda group, compared to 43% in chemotherapy segment. Also a 12-month OS rate of 70.3% in Keytruda group is pitted against 54.8% in chemotherapy. These results injected more confidence in Keytruda as a first-line curative agent for patients with NSCLC.
In a separate press release, the company announced some encouraging results from a phase II study I-SPY 2, evaluating Keytruda in combination with a standard therapy as a neoadjuvant treatment for in patients suffering from triple-negative breast cancer (TNBC).
Data from the study showed that an addition of Keytruda has increased the estimated pathologic complete response (pCR) rate nearly 60% in patients with TNBC, compared to a modest 20% in standard therapy. While in patients with HR+/HER2- breast cancer, the pCR increased by 34% compared to a 13% in standard therapy.
Keytruda is the first anti-PD-1 therapy to gain an FDA approval. The drug is being studied in over 30 types of cancer. Merck is collaborating with several companies like Amgen, Inc. (AMGN - Free Report) , Incyte, GlaxoSmithKline plc (GSK - Free Report) and Pfizer Inc. (PFE - Free Report) for evaluating Keytruda in combination with other regimens.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck's Cancer Drug Keytruda Positive in Clinical Studies
Merck & Co., Inc. (MRK - Free Report) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high levels of PD-L1.
In Aug 2016, Keytruda was approved in the EU for second-line treatment of advanced or metastatic NSCLC in patients with tumors expressing PD-L1 and who have received at least one prior chemotherapy regimen.
Incidentally, the drug is already approved in the U.S. for first-line NSCLC indication. In fact, its sales figures are projected to sharply improve, following the latest approval which would allow Keytruda to be marketed in all 28 member countries of the EU apart from Iceland, Lichtenstein and Norway.
Investors must be reminded that in addition to healing lung cancer, Keytruda is approved in the U.S. for treating patients with unresectable or metastatic melanoma. The drug can be administered until the disease progresses or the toxicity level reaches an unacceptable point.
Also, the medicine comes handy for patients whose previously treated metastatic head and neck cancer (HNSCC) relapses.
Merck’s share price movement shows the stock to outperform the Zacks classified Large Cap Pharma industry in the last year. The stock climbed 14.1% compared to industry’s 2.4% increase during the period.
With approximately eight additional months of follow-up, data from the KEYNOTE-024 study demonstrated a superior overall survival (OS) and progression-free survival (PFS) of Keytruda compared to chemotherapy.
The study showed an 18-month OS rate of 61.2% in the Keytruda group, compared to 43% in chemotherapy segment. Also a 12-month OS rate of 70.3% in Keytruda group is pitted against 54.8% in chemotherapy. These results injected more confidence in Keytruda as a first-line curative agent for patients with NSCLC.
In a separate press release, the company announced some encouraging results from a phase II study I-SPY 2, evaluating Keytruda in combination with a standard therapy as a neoadjuvant treatment for in patients suffering from triple-negative breast cancer (TNBC).
Data from the study showed that an addition of Keytruda has increased the estimated pathologic complete response (pCR) rate nearly 60% in patients with TNBC, compared to a modest 20% in standard therapy. While in patients with HR+/HER2- breast cancer, the pCR increased by 34% compared to a 13% in standard therapy.
Keytruda is the first anti-PD-1 therapy to gain an FDA approval. The drug is being studied in over 30 types of cancer. Merck is collaborating with several companies like Amgen, Inc. (AMGN - Free Report) , Incyte, GlaxoSmithKline plc (GSK - Free Report) and Pfizer Inc. (PFE - Free Report) for evaluating Keytruda in combination with other regimens.
Merck & Company, Inc. Price
Merck & Company, Inc. Price | Merck & Company, Inc. Quote
Zacks Rank
Merck currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>